An analog of AEA in which the alcohol of the ethanolamide group has been replaced with a fluorine atom, which increases the binding affinity and selectivity for the CB1 receptor (Ki = 5.7 nM in rat brain); in vivo activity is enhanced much less than the binding affinity, because the analog is rapidly hydrolyzed by AEA; the addition of an α-methyl group at the C-2 position of arachidonic acid confers enhanced metabolic stability; can fully substitute for Δ9-THC in animal self-administration tests, whereas AEA and 2-fluoro AEA cannot.